1092540-46-9

Usage

Uses

Used in Pharmaceutical Industry:
(S)-2-((R)-2-amino-2-oxo-1-phenylethylamino)-3,3-d9-dimethylbutanamide is used as a key intermediate in the synthesis of deuterated analogs of pharmaceutical compounds. Its deuterated nature may provide enhanced stability and improved pharmacokinetic properties compared to their non-deuterated counterparts.
Used in the Synthesis of Deuterated Analogs:
(S)-2-((R)-2-amino-2-oxo-1-phenylethylamino)-3,3-d9-dimethylbutanamide is used as a starting material for the synthesis of deuterated analogs of various drugs, including the hepatitis C virus protease inhibitor boceprevir. The incorporation of deuterium into the molecular structure can lead to improved metabolic stability and potentially better therapeutic outcomes for patients.
Used in Chemical Research:
(S)-2-((R)-2-amino-2-oxo-1-phenylethylamino)-3,3-d9-dimethylbutanamide can also be utilized in chemical research to study the effects of deuterium substitution on the reactivity, stability, and overall behavior of molecules. This knowledge can be applied to the development of new drugs and materials with enhanced properties.

Upstream product

• 90137-14-7 tert-butylaldehyde-d₉ 
• 1092540-45-8 (R)-2-((S)-1-cyano-2,2-d9-dimethylpropylamino)-2-phenylacetamide 

Downstream Products

• 62965-57-5 (S)-(+)-2-amino-3,3-dimethylbutanamide 
• 1158083-48-7 C₂₀H₁₇⁽²⁾H₁₈N₃O₄ 
• 1092540-48-1 C₆H₄⁽²⁾H₉NO₂*ClH 
• 1158083-37-4 C₁₁H₁₂⁽²⁾H₉NO₄ 

Relevant academic research and scientific papers

Design and synthesis of deuterated boceprevir analogs with enhanced pharmacokinetic properties

As part of an ongoing effort to apply the Deuterated Chemical Entity Platform (DCE Platforma) to clinically validated drugs, the synthesis of deuterated analogs of the hepatitis C virus protease inhibitor boceprevir was carried out. The devised synthetic routes allowed for site-selective deuterium incorporation with high levels of isotopic purity. Application of the DCE Platforma to boceprevir enabled the identification of several deuterated analogs that display marked levels of in vitro metabolic stabilization. Most notably, analog 1g exhibits a near doubling of in vitro half-life in human liver microsomal assays. The details of the convergent synthetic route to the boceprevir isotopologs and the results of the metabolic stability assays are described herein.

Azapeptide derivatives as HIV protease inhibitors

This invention relates to novel compounds of the Formula Ib: that are azapeptides, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel azapeptide compounds that are derivatives of the HIV protease inhibitor atazanavir sulfate. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering HIV protease inhibitors. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving atazanavir.